JP Morgan keeps Overweight on Amneal and Meta, lifts Meta target to $940
Dow Jones Newswires reports JP Morgan kept Overweight ratings on Amneal Pharmaceuticals and Meta Platforms and raised the Meta price target to $940 per share.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Dow Jones Newswires reported that JP Morgan kept its Overweight rating on Amneal Pharmaceuticals shares. Separately, the agency said the bank also maintained Overweight on Meta Platforms and raised its price target to $940 per share from $920.
why it matters
Analyst decisions like these rarely move the market on their own, but the higher Meta target suggests the bank is more bullish on the stock than before. For investors, such revisions mainly serve as a gauge of sentiment around the companies rather than a standalone signal.
tags
instruments
sources
- Amneal Pharmaceuticals Is Maintained at Overweight by JP Morgan — Dow Jones Newswires, 22 October 2026 at 13:49 UTC
- Meta Platforms Is Maintained at Overweight by JP Morgan — Dow Jones Newswires, 22 October 2026 at 14:02 UTC
- AT&T Is Maintained at Overweight by JP Morgan — Dow Jones Newswires, 22 October 2026 at 14:08 UTC
- JBS Is Maintained at Overweight by JP Morgan — Dow Jones Newswires, 22 October 2026 at 14:13 UTC
- Murphy USA Is Maintained at Overweight by JP Morgan — Dow Jones Newswires, 22 October 2026 at 14:29 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗